Get the Stockscreener App
0.576
5.11%
0.028
After Hours:
.58
0.004
+0.69%
Athira Pharma Inc stock is traded at $0.576, with a volume of 221.72K.
It is up +5.11% in the last 24 hours and down -10.32% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
See More
Previous Close:
$0.548
Open:
$0.5455
24h Volume:
221.72K
Relative Volume:
0.05
Market Cap:
$22.27M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.2035
EPS:
-2.83
Net Cash Flow:
$-101.06M
1W Performance:
-1.52%
1M Performance:
-10.32%
6M Performance:
-74.85%
1Y Performance:
-72.57%
1-Day Range:
$0.52
$0.576
1-Week Range:
$0.52
$0.609
52-Week Range:
$0.4115
$4.2984
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.576 | 22.27M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Athira Pharma Insider Ups Holding By 111% During Year - Yahoo Finance
Athira Pharma's SWOT analysis: stock faces challenges after trial setback - Investing.com
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND - GlobeNewswire
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by GSA Capital Partners LLP - Defense World
Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail
Athira Pharma's SWOT analysis: stock shifts focus after trial setback By Investing.com - Investing.com UK
Athira Pharma's SWOT analysis: stock shifts focus after trial setback - Investing.com
Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline - MSN
Athira exploring strategic alternatives after Alzheimer’s failure - BioPharma Dive
Athira Pharma Reports Q3 2024 Financial Results - TipRanks
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - The Manila Times
What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register
Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360
US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN
Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan
Athira Pharma faces Nasdaq delisting over share price - Investing.com
A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News
A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News
A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily
Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily
Check out these key findings about Athira Pharma Inc (ATHA) - SETE News
Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News
Athira Pharma to lay off 70% of workforce - PharmaLive
Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily
Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex
Athira Pharma to Lay Off 70% of Workforce - BioSpace
After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule - Fierce Biotech
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada
Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily
Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com
Athira Pharma downgraded to Neutral from Outperform at Mizuho - TipRanks
Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World
Taking the lead: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals
Athira Pharma to Cut About 70% of Workforce - MarketWatch
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gengos Andrew | CFO and Chief Business Officer |
Sep 05 '24 |
Sale |
0.57 |
1,272 |
720 |
97,532 |
| Lenington Rachel | COO and CDO |
Sep 05 '24 |
Sale |
0.57 |
2,525 |
1,429 |
20,870 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Sep 05 '24 |
Sale |
0.57 |
2,525 |
1,429 |
92,684 |
| Worthington Mark | GENERAL COUNSEL |
Sep 05 '24 |
Sale |
0.57 |
2,525 |
1,429 |
51,927 |
| Litton Mark James | President and CEO |
Sep 05 '24 |
Sale |
0.57 |
5,032 |
2,848 |
159,365 |
| Romano Kelly A | Director |
Jun 24 '24 |
Buy |
2.42 |
27,400 |
66,179 |
80,715 |
| Romano Kelly A | Director |
Jun 21 '24 |
Buy |
2.26 |
15,000 |
33,872 |
53,315 |
| Litton Mark James | Chief Executive Officer |
Jan 05 '24 |
Sale |
2.91 |
4,820 |
14,026 |
144,397 |
| Worthington Mark | General Counsel |
Jan 05 '24 |
Sale |
2.91 |
2,412 |
7,019 |
34,452 |
| Lenington Rachel | Chief Operating Officer |
Jan 05 '24 |
Sale |
2.91 |
2,412 |
7,019 |
13,395 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):